CA Patent

CA3094551A1 — Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof

Assigned to Pharos Ltd · Expires 2019-10-31 · 7y expired

What this patent protects

The present invention relates to an extended release pharmaceutical composition for oral administration comprising a therapeutically effective quantity of fesoterodine or a pharmaceutically acceptable salt, metabolite or derivative thereof, as an active ingredient, an effective q…

USPTO Abstract

The present invention relates to an extended release pharmaceutical composition for oral administration comprising a therapeutically effective quantity of fesoterodine or a pharmaceutically acceptable salt, metabolite or derivative thereof, as an active ingredient, an effective quantity of glycerol dibehenate as a stabilizing agent in order to prevent the degradation and improve the physicochemical stability of the active ingredient in the finished dosage form and at least one pharmaceutically acceptable excipient as a rate controlling agent to modify/control the release of the active ingredient in the finished dosage form.

Drugs covered by this patent

Patent Metadata

Patent number
CA3094551A1
Jurisdiction
CA
Classification
Expires
2019-10-31
Drug substance claim
No
Drug product claim
No
Assignee
Pharos Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.